home · filing · 0001193125-21-218690
8-K filed July 19, 2021, 7:59 PM ET
ticker PRLD
CIK 0001678660
leadership
confidence high
sentiment neutral
materiality 0.25
Prelude Therapeutics appoints Martin Babler as Class II director, effective July 19, 2021
Prelude Therapeutics Inc
Martin Babler appointed to Board as Class II director and Audit Committee member, effective July 19, 2021.
Babler previously President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020.
Received non-incentive stock options for 36,400 shares vesting monthly over three years under 2020 Equity Incentive Plan.
Will receive standard non-employee director compensation and enter into customary indemnity agreement.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-07-19
Filed July 19, 2021, 7:59 PM ET
the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Martin Babler was appointed as Class II director at Prelude Therapeutics Inc.
Action appointed
Role Class II director
Exact text from the filing
the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-218690
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.